Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine vs Paxlovid in severe and critical COVID-19
ChiCTR2300068643Phase 4Recruiting
- Sponsor
- Xiang'an Hospital of Xiamen University
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Routine treatment + azvudine with Routine treatment + Paxlovid (2 arms). Primary endpoint: 28-day survival rate. Started Jan 2023; status: recruiting.
02
Drugs
azvudineNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300068643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068643.